Table 4.

Changes in renal measures

Measure1-Year Retrospective VisitP ValueBaseline VisitP Value1-Year Follow-Up Visit
Agalsidase-beta regular-dose group
 Albumin-to-creatinine ratio (mg/g creatinine) (n=35)155 (4–369)0.80173 (0–375)0.4697 (5–283)
 Cystatin C GFR (ml/min per 1.73 m2) (n=22)91 (21–125)0.44104 (18–158)0.98101 (49–151)
 eGFR (CKD-EPI) (ml/min/1.73 m2) (n=37)98 (64–120)0.2599 (63–119)0.49101 (58–120)
 Creatinine (mg/dl) (n=37)0.91 (0.70–3.10)0.320.89 (0.50–3.40)0.240.83 (0.60–1.30)
 Hemoglobin (mg/dl) (n=33)13.7±1.40.8113.8±1.20.7613.6±1.5
 Dialysis, n (%)6 (16)1.006 (16)1.007 (18)
 Kidney transplant, n (%)1 (2.6)1.001 (2.6)1.001 (2.6)
Agalsidase-beta dose-reduction group
 Albumin-to-creatinine ratio (mg/g creatinine) (n=32)231 (0–1807)0.58273 (0–1010)0.27239 (0–1420)
 Cystatin-C GFR (ml/min per 1.73 m2) (n=13)96 (35–132)0.33109 (65–132)0.0292 (69–135)
 eGFR (CKD-EPI) (ml/min per 1.73 m2) (n=27)94 (61–116)0.3498 (86–114)0.0195 (82–114)
 Creatinine (mg/dl) (n=26)0.85 (0.70–2.70)0.570.80 (0.60–1.20)0.600.80 (0.70–1.00)
 Hemoglobin (mg/dl) (n=25)13.3±1.40.2713.6±1.20.5013.5±1.2
 Dialysis, n (%)5 (17)1.005 (17)1.005 (17)
 Kidney transplant, n (%)4 (14)1.005 (17)1.005 (17)
Agalsidase-alfa switch group
 Albumin-to-creatinine ratio (mg/g creatinine) (n=36)40 (0–1292)0.37114 (0–606)0.03216 (0–2062)
 Cystatin-C GFR (ml/min per 1.73m2) (n=23)108 (53–130)0.47101 (52–151)0.0996 (64–141)
 eGFR (CKD-EPI) (n=37) (ml/min per 1.73 m2)99 (68–123)0.5399 (66–112)0.0595 (64–116)
 Creatinine (mg/dl) (n=37)0.88 (0.50–1.40)0.060.87 (0.60–2.30)0.180.83 (0.60–1.20)
 Hemoglobin (mg/dl) (n=36)13.6±1.30.0913.4±1.30.2413.6±1.1
 Dialysis, n (%)5 (13)1.005 (13)1.005 (13)
 Kidney transplant, n (%)3 (8)1.003 (8)1.003 (8)
  • Categorical data are presented as number (percentage) of patients. Otherwise data are presented as median (range) or mean±SD. For eGFR analyses, all patients with hyperfiltration (125–175 ml/min per 1.73 m2) and undergoing dialysis were excluded. CKD-EPI, CKD–Epidemiology Collaboration.